top of page

Vaccine Development
& Global Implementation

A Static Infographic Poster + An interactive Data Visualization

This project is aimed to engage public interest in vaccine development and the global effort to combat infectious diseases. It consists of an infographic poster and an interactive wall display. 

The poster takes Gardasil – an HPV vaccine – as an example, to explain each crucial and necessary stage it takes, for a novel vaccine to be approved for use in the market. To see how long it takes to make a vaccine, the infographic also includes a comprehensive development timeline for each vaccine preventable disease.


To illustrate whether vaccine was efficient in controlling the disease, the interactive module contains a comparison between disease incidence and vaccination coverage. It also lists the global coverage of a vaccine based on whether a country has set up a vaccination schedule for a particular disease. 

Infographic Poster

 27" x 36" in size 

Vaccine development infographics - Mimi Guo.png

Interactive Mockup Demo

 40" x 25" Wall Display

Faculty advisor

Dr. Jodie Jenkinson


Adobe Illustrator

Final presentation format

Infographic: 27 x 36 inches wall poster

Interactive wall display: 40 x 25 inches

Primary audience

Lay audience

Work Process

1. Ideation

I always wanted to design a beautiful graphic for people to get to know the drug development process. During my co-op time in a pharmaceutical company, I realize that this is a very streamlined but complicated process that few people know of. It's important for the public to understand what effort goes into developing vaccines and medications so that people can trust the product. A clear and engaging visual is needed to help people digest all the information related. 



  1. Shi, L., Sings, H. L., Bryan, J. T., Wang, B., Wang, Y., Mach, H., Kosinski, M., Washabaugh, M. W., Sitrin, R. Barr, E. (2006). GARDASIL®: Prophylactic Human Papillomavirus Vaccine Development – From Bench Top to Bed‐side. Clinical Pharmacology & Therapeutics, 81(2), 259-264. doi:10.1038/sj.clpt.6100055

  2. Cunningham, A. L., Garcon, N., Leo, O., Friedland, L. R., Strugnell, R., Laupèze, B., Doherty, M., & Stern, P. (2016). Vaccine development: From concept to early clinical testing. Vaccine, 34(52), 6655-6664.

  3. Callaway, E., (2020, April 28). The race for coronavirus vaccines: a graphical guide. Nature News Feature.

  4. Siddiqui, M. A. A., & Perry, C. M. (2006). Human Papillomavirus Quadrivalent (types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®). Drugs, 66(9), 1263-1271.

  5. Villa, L. L., Costa, R. L., & Petta, C. A. et al. (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. The Lancet Oncology, 6(5), 271-278.

  6. Buckland, B. C. (2005). The process development challenge for a new vaccine. Nature Medicine, 11, S16-S19.

  7. Block, S. L., Brown, D. R., & Chatterjee, A. et al. (2010). Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine. The Pediatric Infectious Disease Journal, 29(2), 95-101. doi: 10.1097/INF.0b013e3181b77906.

  8. Serdobova, I. & Kieny, MP. (2011). Assembling a Global Vaccine Development Pipeline for Infectious Diseases in the Developing World. American Journal of Public Health, 96, 1554-1559.

bottom of page